SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Eli Lilly's biotechnology center in San
Business
Lilly’s Mounjaro Beats Q3 Expectations, But Company Cuts Full-Year Profit Guidance
Sales of type 2 diabetes treatment Mounjaro brought in $1.4 billion in the third quarter. However, the company cut its full-year profit guidance due to charges mainly related to recent acquisitions.
November 2, 2023
 · 
1 min read
 · 
Kate Goodwin
External view of AstraZeneca's production plant in Sweden
Business
AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis
The investment in the French biotech is one of many the pharma giant has made this year to advance cell and gene therapy development. Cellectis shares skyrocketed over 180% in premarket trading Wednesday.
November 1, 2023
 · 
2 min read
 · 
Kate Goodwin
A researcher at work in a Novavax laboratory/Novav
FDA
Combination Vaccines Are Coming for Respiratory Diseases
Pfizer, Moderna, Novavax and more are working to combine preventative shots for COVID-19, flu, RSV and other illnesses. Will convenience be enough to overcome vaccine fatigue?
October 31, 2023
 · 
4 min read
 · 
Kate Goodwin
Pictured: Amgen's office in Massachusetts/iStock,
Business
Amgen Axes Prostate Cancer Drug, Takes $650M Write-Down as Q3 Profit Drops
In its third-quarter results Tuesday, Amgen announced a $650 million write-down after discontinuing AMG 340, a prostate cancer candidate acquired in the $900 million buy of Tenobio in 2021.
October 31, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Sanofi Distribution Center
Business
Sanofi Plans Spin-Off of Consumer Business, Lowers Profit Outlook
The French drugmaker’s shares dropped more than 15% Friday morning on the announcement that it has abandoned its goal of a 32% operating profit margin for 2025, focusing on long-term profitability.
October 27, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Takeda Pharmaceutical sign/iStock, jetci
Business
Takeda Reports $770M Write-Down, Cuts Profit Forecast by 71% for FY2023
Attributing losses to exchange rate and pipeline impairment losses, the Japanese biopharma dropped its reported net profit forecast of 142 billion yen ($945.1 million) to 93 billion yen ($618.8 million).
October 26, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Alzheimer's disease illustration/iStock,
Drug Development
Araclon’s Alzheimer’s Vaccine Shows Clean Safety Profile in Phase II Analysis
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
October 25, 2023
 · 
2 min read
 · 
Kate Goodwin
A DNA strand being transcribed into mRNA/iStock, s
FDA
Medicine’s Hot New Modality, mRNA, Faces Unclear Regulatory Landscape
Even after the runaway success of mRNA vaccines against COVID-19, the pathway to approval for upcoming would-be mRNA therapeutics has yet to be laid out.
October 24, 2023
 · 
5 min read
 · 
Kate Goodwin
Pictured: Facade of Novartis building in Switzerland
Business
Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance
The Swiss pharma reported a 12% sales increase and 21% core operating growth for the third quarter on Tuesday, while raising its full-year earnings forecast for the third time.
October 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Amgen's office in Tampa, Florida
Drug Development
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
Tarlatamab achieved a 40% objective response rate in small cell lung cancer patients with advanced disease who had failed two or more prior lines of treatment, the company announced Friday.
October 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Handshake over a deal/iStock, PeopleImag
Royalty Boosts Struggling PTC with Additional $1B for Royalties on Roche’s Evrysdi
The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.
October 19, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Doctor diagnosing lungs on screen/iStock
Drug Development
Ultimovacs Rebounds on New Universal Cancer Vaccine Data for Mesothelioma
After failing its primary endpoint of progression-free survival, new data shows UV1 plus Bristol Myers Squibb’s Opdivo and Yervoy reduces risk of death by 27% over the checkpoint inhibitors alone.
October 18, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Finger pressing pause button/iStock, cag
Drug Development
Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA
The biotech will pause its lirafugratinib program for a rare bile duct cancer to target a larger FGFR2-altered solid tumors population, citing the Inflation Reduction Act as a driving decision factor.
October 13, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Eli Lilly World Headquarters/iStock, jet
Drug Development
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
More than 54% of patients treated with mirikizumab achieved clinical remission at 52 weeks versus 19.6% of those on placebo. Eli Lilly will submit a marketing application in Crohn’s disease to the FDA in 2024.
October 12, 2023
 · 
1 min read
 · 
Kate Goodwin
Pictured: Roche Diagnostics building in California
Drug Development
Roche’s Subcutaneous Ocrevus Rivals IV Formulation in Phase III MS Trial
The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.
October 11, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More